Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System
Bio-Techne (NASDAQ: TECH) has launched Leo™, a next-generation Simple Western™ system that significantly enhances protein analysis capabilities. The system can process up to 100 samples in a single 3-hour run, delivering 4x higher throughput than the Jess™ system and 5x faster processing than Sally Sue™ and Peggy Sue™ systems.
Leo features enhanced Compass Software with advanced analysis capabilities and improved 21 CFR Part 11 Compliance support. The system offers experimental size, precision, and reproducibility suitable for regulatory submissions. Beta testers have praised Leo's robust performance and versatility across applications including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control, and recombinant protein expression.
Bio-Techne (NASDAQ: TECH) ha lanciato Leo™, un sistema Simple Western™ di nuova generazione che migliora notevolmente le capacità di analisi delle proteine. Il sistema può elaborare fino a 100 campioni in un'unica corsa di 3 ore, offrendo un throughput 4 volte superiore rispetto al sistema Jess™ e una velocità di elaborazione 5 volte superiore rispetto ai sistemi Sally Sue™ e Peggy Sue™.
Leo è dotato di Compass Software avanzato con capacità di analisi migliorate e supporto per la conformità alla parte 11 del 21 CFR. Il sistema offre dimensioni sperimentali, precisione e riproducibilità adatte per le presentazioni regolatorie. I beta tester hanno lodato le prestazioni robuste e la versatilità di Leo in applicazioni che includono la degradazione mirata delle proteine, studi sui biomarcatori clinici, saggi di potenza della terapia genica, controllo qualità e espressione di proteine ricombinanti.
Bio-Techne (NASDAQ: TECH) ha lanzado Leo™, un sistema Simple Western™ de nueva generación que mejora significativamente las capacidades de análisis de proteínas. El sistema puede procesar hasta 100 muestras en una sola corrida de 3 horas, ofreciendo un rendimiento 4 veces superior al sistema Jess™ y un procesamiento 5 veces más rápido que los sistemas Sally Sue™ y Peggy Sue™.
Leo cuenta con un software Compass mejorado con capacidades de análisis avanzadas y un mejor soporte para el cumplimiento de la parte 11 del 21 CFR. El sistema ofrece un tamaño experimental, precisión y reproducibilidad adecuados para presentaciones regulatorias. Los beta testers han elogiado el rendimiento robusto y la versatilidad de Leo en aplicaciones que incluyen degradación de proteínas dirigida, estudios de biomarcadores clínicos, ensayos de potencia de terapia génica, control de calidad y expresión de proteínas recombinantes.
Bio-Techne (NASDAQ: TECH)는 단백질 분석 능력을 크게 향상시키는 차세대 Simple Western™ 시스템인 Leo™를 출시했습니다. 이 시스템은 3시간 동안 최대 100개의 샘플을 처리할 수 있으며, Jess™ 시스템보다 4배 높은 처리량과 Sally Sue™ 및 Peggy Sue™ 시스템보다 5배 빠른 처리 속도를 제공합니다.
Leo는 향상된 분석 기능과 개선된 21 CFR Part 11 준수 지원을 갖춘 Compass Software를 특징으로 합니다. 이 시스템은 규제 제출에 적합한 실험 크기, 정밀도 및 재현성을 제공합니다. 베타 테스터들은 타겟 단백질 분해, 임상 바이오마커 연구, 유전자 치료 효능 시험, 품질 관리 및 재조합 단백질 발현을 포함한 다양한 응용 분야에서 Leo의 강력한 성능과 다재다능성을 칭찬했습니다.
Bio-Techne (NASDAQ: TECH) a lancé Leo™, un système Simple Western™ de nouvelle génération qui améliore considérablement les capacités d'analyse des protéines. Le système peut traiter jusqu'à 100 échantillons en une seule course de 3 heures, offrant un débit 4 fois supérieur à celui du système Jess™ et un traitement 5 fois plus rapide que les systèmes Sally Sue™ et Peggy Sue™.
Leo est doté d'un logiciel Compass amélioré avec des capacités d'analyse avancées et un meilleur support pour la conformité à la partie 11 du 21 CFR. Le système offre une taille expérimentale, une précision et une reproductibilité adaptées aux soumissions réglementaires. Les testeurs bêta ont salué la performance robuste et la polyvalence de Leo dans des applications telles que la dégradation ciblée des protéines, les études de biomarqueurs cliniques, les essais de puissance de thérapie génique, le contrôle qualité et l'expression de protéines recombinantes.
Bio-Techne (NASDAQ: TECH) hat Leo™ eingeführt, ein System der nächsten Generation für Simple Western™, das die Fähigkeiten zur Proteinanalyse erheblich verbessert. Das System kann bis zu 100 Proben in einem einzigen 3-Stunden-Durchlauf verarbeiten und bietet eine 4-fach höhere Durchsatzrate als das Jess™-System und eine 5-fach schnellere Verarbeitung als die Systeme Sally Sue™ und Peggy Sue™.
Leo verfügt über verbesserte Compass-Software mit erweiterten Analysefähigkeiten und verbessertem Support für die Einhaltung von 21 CFR Teil 11. Das System bietet experimentelle Größen, Präzision und Reproduzierbarkeit, die für regulatorische Einreichungen geeignet sind. Beta-Tester haben die robuste Leistung und Vielseitigkeit von Leo in Anwendungen wie gezielte Proteinabbau, klinische Biomarker-Studien, Wirksamkeitsprüfungen von Gentherapien, Qualitätskontrolle und rekombinanter Proteinexpression gelobt.
- 4x higher throughput capacity compared to previous Jess™ system
- 5x faster processing times than existing Sally Sue™ and Peggy Sue™ systems
- Improved regulatory compliance with enhanced 21 CFR Part 11 support
- Expanded application capabilities for bioanalytical workflows
- None.
Insights
Bio-Techne's launch of the Leo™ System represents a significant technological advancement in protein analysis automation that could meaningfully impact the company's competitive position. The 4x throughput improvement and 5x faster turnaround times compared to their previous systems transform what was traditionally a bottleneck in laboratory workflows. This level of improvement isn't merely incremental - it potentially changes the economics of protein analysis by allowing labs to process up to 100 samples in 3 hours.
The enhanced Compass software with improved 21 CFR Part 11 Compliance directly targets regulated environments like pharmaceutical development and manufacturing, where documentation and data integrity are critical. This strategic positioning opens doors to higher-value markets with more stringent requirements and typically higher margins.
Most noteworthy is the system's application versatility across targeted protein degradation, clinical biomarkers, gene therapy potency assays, and quality control workflows. This broad utility expands the potential customer base beyond traditional research settings into clinical and manufacturing environments. For protein-based therapeutics developers, the ability to accelerate potency assays and quality control testing directly impacts time-to-market for biologic drugs.
The technology appears to maintain the automated western blot workflow that made previous Simple Western systems valuable while dramatically improving throughput - essentially offering ELISA-like productivity with western blot specificity, potentially disrupting traditional protein quantitation workflows.
This product launch strengthens Bio-Techne's position in the protein analysis instrumentation market with potential positive revenue implications. The Leo system represents the latest evolution of their Simple Western platform, which has been a growth driver in their Protein Sciences segment.
The 4x throughput improvement creates a compelling upgrade proposition for existing customers while potentially attracting new users seeking efficiency gains. Scientific instruments typically follow a razor/razor blade business model, where initial system placements drive ongoing consumable purchases with higher margins. Each Leo placement likely represents a multi-year revenue stream beyond the initial capital purchase.
The enhanced regulatory compliance features strategically position the system for pharmaceutical and biotechnology customers, who typically have larger budgets and more stable spending patterns than academic institutions. The emphasis on applications in therapeutic development (gene therapy potency assays, targeted protein degradation) aligns with growing biopharmaceutical research areas.
While no pricing details are provided, laboratory automation systems in this category typically command
The timing is favorable as life sciences companies seek automation solutions to address labor challenges and accelerate development timelines. Without specific sales projections, the financial impact remains somewhat uncertain, but the substantial performance improvements suggest this could become a meaningful contributor to the Protein Sciences segment over the next several quarters as adoption increases.
Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.
"With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments," commented Will Geist, President of Bio-Techne's Protein Sciences Segment. "Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster."
Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument's robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more.
Explore Leo's capabilities at bio-techne.com/leo. Data on Leo's performance will be presented at an upcoming webinar. Registration details can be found here.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-begins-shipping-leo---a-next-generation-high-throughput-simple-western-system-302395190.html
SOURCE Bio-Techne Corporation
FAQ
What are the key features of Bio-Techne's (TECH) new Leo system?
How much faster is TECH's Leo system compared to previous models?
What applications does Bio-Techne's (TECH) Leo system support?
How does TECH's Leo system improve regulatory compliance?
